# AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

Source: https://onco.cc/trials/nct06646055/  
OnCo record `nct06646055` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Ivonescimab, Cadonilimab, Paclitaxel / nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Akeso, active and no longer recruiting.

## Summary

AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer is a phase 1/2 interventional study registered as NCT06646055 by Akeso, with 110 participants planned, started 2025-01-21 and due to reach its primary completion in 2026-12-30. Interventions recorded: AK112, Cadonilimab, nab-paclitaxel, gemcitabine, AK112, Cadonilimab, nab-paclitaxel, gemcitabine, AK112, Cadonilimab, nab-paclitaxel, gemcitabine, AK112, nab-paclitaxel, gemcitabine, nab-paclitaxel, gemcitabine. Conditions listed: Metastatic Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06646055
- Phase: 1/2
- Setting: A Phase Ib/II Clinical Study of AK112 and Cadonilimab Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Cancer
- Sponsor: Akeso
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT06646055: https://clinicaltrials.gov/study/NCT06646055

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Cadonilimab](https://onco.cc/drugs/cadonilimab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct06646055.json